Clinical presentations of COVID-19 are highly variable, yet the precise mechanisms that govern the pathophysiology of different disease courses remain poorly defined. Across the spectrum of disease severity, COVID-19 impairs both innate and adaptive host immune responses by activating innate immune cell recruitment, while resulting in low lymphocyte counts. Recently, several reports have shown that patients with severe COVID-19 exhibit a dysregulated myeloid cell compartment, with increased myeloid-derived suppressor cells (MDSCs) correlating with disease severity. MDSCs, in turn, promote virus survival by suppressing T-cell responses and driving a highly pro-inflammatory state through the secretion of various mediators of immune activation. Here, we summarize the evidence on MDSCs and myeloid cell dysregulation in COVID-19 infection and discuss the potential of MDSCs as biomarkers and therapeutic targets in COVID-19 pneumonia and associated disease.
【저자키워드】 COVID-19, immunology, Biomarkers, Immunity, MDSC, 【초록키워드】 COVID-19 pneumonia, Biomarker, Biomarkers, adaptive, severe COVID-19, Pneumonia, disease severity, T-cell Response, virus, lymphocyte, survival, Host immune response, COVID-19 infection, pathophysiology, immune activation, clinical, immune responses, Patient, recruitment, Spectrum, disease, mechanism, therapeutic targets, T-cell responses, Evidence, therapeutic target, mediators, dysregulation, suppressor cells, Clinical presentations, secretion, disease course, lymphocyte counts, driving, myeloid cell, pro-inflammatory state, Cell, defined, shown, resulting, promote, dysregulated, turn, impair, activating, innate immune cell, 【제목키워드】 target, suppressor cells, suppressor, Potential,